Urogen Pharma (NASDAQ:URGN) General Counsel Sells $64,618.26 in Stock

Posted by Francis Steltz on Sep 9th, 2026

Urogen Pharma (NASDAQ:URGN – Get Free Report) General Counsel Jason Smith sold 1,519 shares of the stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $42.54, for a total transaction of $64,618.26. Following the completion of the transaction, the general counsel directly owned 53,141 shares of the company’s stock, valued at approximately $2,260,618.14. This trade represents a 2.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Urogen Pharma Trading Up 1.8%

Shares of NASDAQ:URGN traded up $0.79 during trading on Wednesday, hitting $44.60. 648,104 shares of the stock were exchanged, compared to its average volume of 807,203. The company has a fifty day moving average price of $43.02 and a two-hundred day moving average price of $31.15. The company has a market cap of $2.18 billion, a PE ratio of -22.61 and a beta of 1.57. Urogen Pharma has a 12-month low of $15.86 and a 12-month high of $50.81.

Urogen Pharma (NASDAQ:URGN – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The company had revenue of $72.46 million during the quarter, compared to analysts’ expectations of $63.55 million. Equities research analysts anticipate that Urogen Pharma will post -0.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on URGN. TD Cowen lifted their price target on Urogen Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. UBS Group restated a “buy” rating on shares of Urogen Pharma in a report on Thursday, July 9th. HC Wainwright lifted their target price on shares of Urogen Pharma from $45.00 to $75.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Friday, July 17th. Finally, Guggenheim raised their price objective on shares of Urogen Pharma from $42.00 to $58.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Urogen Pharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.38.

Read Our Latest Research Report on Urogen Pharma

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its stake in shares of Urogen Pharma by 347.5% during the 1st quarter. AQR Capital Management LLC now owns 114,066 shares of the company’s stock worth $1,262,000 after purchasing an additional 88,577 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Urogen Pharma by 7.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock valued at $258,000 after buying an additional 1,653 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of Urogen Pharma by 94.3% during the first quarter. Jane Street Group LLC now owns 51,177 shares of the company’s stock valued at $566,000 after buying an additional 24,839 shares during the period. Cetera Investment Advisers acquired a new stake in Urogen Pharma during the second quarter worth approximately $361,000. Finally, JPMorgan Chase & Co. boosted its position in Urogen Pharma by 5.2% during the second quarter. JPMorgan Chase & Co. now owns 390,364 shares of the company’s stock worth $5,348,000 after acquiring an additional 19,405 shares during the last quarter. Institutional investors and hedge funds own 91.29% of the company’s stock.

Urogen Pharma Company Profile

(Get Free Report)

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.